EP1893750A4 - Amniotic cells and methods for use thereof - Google Patents

Amniotic cells and methods for use thereof

Info

Publication number
EP1893750A4
EP1893750A4 EP06753014A EP06753014A EP1893750A4 EP 1893750 A4 EP1893750 A4 EP 1893750A4 EP 06753014 A EP06753014 A EP 06753014A EP 06753014 A EP06753014 A EP 06753014A EP 1893750 A4 EP1893750 A4 EP 1893750A4
Authority
EP
European Patent Office
Prior art keywords
methods
amniotic cells
amniotic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06753014A
Other languages
German (de)
French (fr)
Other versions
EP1893750A1 (en
Inventor
Lihe Guo
Tianjin Liu
Jiacai Wu
Xuesong Wang
Zhihua Jiang
Qin Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELL STAR BIO-TECHNOLOGIES Co Ltd
CELL STAR BIO TECHNOLOGIES CO
Original Assignee
CELL STAR BIO-TECHNOLOGIES Co Ltd
CELL STAR BIO TECHNOLOGIES CO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELL STAR BIO-TECHNOLOGIES Co Ltd, CELL STAR BIO TECHNOLOGIES CO filed Critical CELL STAR BIO-TECHNOLOGIES Co Ltd
Publication of EP1893750A1 publication Critical patent/EP1893750A1/en
Publication of EP1893750A4 publication Critical patent/EP1893750A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
EP06753014A 2005-06-24 2006-06-23 Amniotic cells and methods for use thereof Withdrawn EP1893750A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2005100271288A CN1884495A (en) 2005-06-24 2005-06-24 Human amnion cell capable of expressing extraneous gene and its preparation method and uses
PCT/CN2006/001437 WO2006136114A1 (en) 2005-06-24 2006-06-23 Amniotic cells and methods for use thereof

Publications (2)

Publication Number Publication Date
EP1893750A1 EP1893750A1 (en) 2008-03-05
EP1893750A4 true EP1893750A4 (en) 2009-05-13

Family

ID=37570119

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06753014A Withdrawn EP1893750A4 (en) 2005-06-24 2006-06-23 Amniotic cells and methods for use thereof

Country Status (7)

Country Link
EP (1) EP1893750A4 (en)
JP (1) JP2008543319A (en)
KR (1) KR20080025173A (en)
CN (1) CN1884495A (en)
AU (1) AU2006261485A1 (en)
CA (1) CA2620946A1 (en)
WO (1) WO2006136114A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514567D0 (en) * 2005-07-15 2005-08-24 Univ Nottingham Surgical membrane
EP2067858A1 (en) * 2007-12-07 2009-06-10 Universidad de Sevilla Animal models for neurodegenerative diseases
CN101721430B (en) * 2008-10-22 2013-01-23 中美赛傲(上海)生物技术有限公司 Application of amniotic epithelial cells in pharmacy
CN103705979B (en) * 2013-09-18 2016-10-05 中国人民解放军海军总医院 For functional organization's engineering material of CO2 laser weld and preparation thereof and purposes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056022A2 (en) * 2001-12-21 2003-07-10 Oxford Biomedica (Uk) Limited Method for producing a transgenic organism using a lentiviral expression vector such as eiav
WO2004000164A2 (en) * 2002-06-24 2003-12-31 Amniotech, Inc. Amniotic membrane mediated delivery of bioactive molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3806189B2 (en) * 1995-07-27 2006-08-09 株式会社エスアールエル Methods for gene transfer into human amniotic cells and methods for preparing cells for gene therapy
JP4217037B2 (en) * 2001-08-10 2009-01-28 宣男 櫻川 Human neural stem cells derived from human amnion mesenchymal cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056022A2 (en) * 2001-12-21 2003-07-10 Oxford Biomedica (Uk) Limited Method for producing a transgenic organism using a lentiviral expression vector such as eiav
WO2004000164A2 (en) * 2002-06-24 2003-12-31 Amniotech, Inc. Amniotic membrane mediated delivery of bioactive molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUCHSCHACHER G L ET AL: "DEVELOPMENT OF LENTIVIRAL VECTORS FOR GENE THERAPY FOR HUMAN DISEASES", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 8, 1 January 2000 (2000-01-01), pages 2499 - 2504, XP000916373, ISSN: 0006-4971 *
KOSUGA MOTOMICHI ET AL: "Phenotype correction in murine mucopolysaccharidosis type VII by transplantation of human amniotic epithelial cells after adenovirus-mediated gene transfer", CELL TRANSPLANTATION, vol. 9, no. 5, September 2000 (2000-09-01), pages 687 - 692, XP009114244, ISSN: 0963-6897 *
LIU TIANJIN ET AL: "Human amniotic epithelial cells ameliorate behavioral dysfunction and reduce infarct size in the rat middle cerebral artery occlusion model.", SHOCK (AUGUSTA, GA.) MAY 2008, vol. 29, no. 5, May 2008 (2008-05-01), pages 603 - 611, XP009114219, ISSN: 1073-2322 *
See also references of WO2006136114A1 *
TAKAHASHI SATORU ET AL: "A novel approach to ex vivo gene therapy for familial hypercholesterolemia using human amniotic epithelial cells as a transgene carrier", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 4, April 2001 (2001-04-01), pages 279 - 292, XP002520718, ISSN: 0040-8727 *

Also Published As

Publication number Publication date
KR20080025173A (en) 2008-03-19
WO2006136114A1 (en) 2006-12-28
CN1884495A (en) 2006-12-27
JP2008543319A (en) 2008-12-04
AU2006261485A1 (en) 2006-12-28
EP1893750A1 (en) 2008-03-05
CA2620946A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
EP1909097A4 (en) Biosensor and biosensor cell
EP1977359A4 (en) Methods and systems for conducting research operations
TWI316307B (en) Case for batteries and preparation method thereof
SI1780267T1 (en) Amniotic fluid derived cells
IL228770A0 (en) Processes and intermaediates
EP1910736A4 (en) Etendue-conserving illumination-optics for backlights and frontlights
EP1952458A4 (en) High capacity electrode and methods for its fabrication and use
IL185783A0 (en) Accumulator and method for the operation thereof
EP1909342A4 (en) Battery can and method for manufacturing same
IL211089A0 (en) Compositions and methods for cell killing
EP2051313A4 (en) Battery can and battery using the same
IL184262A (en) Cell culture method
GB0509833D0 (en) Cell analysis
GB0517382D0 (en) Cell culture
EP1860711A4 (en) Enclosed battery
ZA200703293B (en) Cell bandage
EP1871914A4 (en) Methods and compositions for introducing biopolymers into cells
ZA200805080B (en) Methods and compositions for expanding T regulatory cells
EP1897159A4 (en) Lead-alkaline battery
GB0503918D0 (en) Cell
EP1781337A4 (en) Methods and compositions for cell activation
EP1893750A4 (en) Amniotic cells and methods for use thereof
EP1907533A4 (en) Progenitor cells and uses thereof
EP1807508A4 (en) Methods for preparing cells and viruses
TWI366941B (en) Electrolyte containing oxocarbons and its use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090715